Abstract:Object:This study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1-2, as well as the potential impact of hyperuricemia (HUA) on these factors in CKD stage 1-2 patients.Methods:In this study, fecal samples were collected from CKD stage 1-2 without HUA patients (CKD-N group), CKD stage 1-2 with HUA patients (CKD-H group), and healthy people controls (HCs group). The samples were then subjected to the microbiome (16S rRNA gene sequencing) and metabolome (liquid chromatography-tandem mass spectrometry) analyses. The multi-omics datasets were analyzed individually and integrated for combined analysis using various bioinformatics approaches.Results:Gut microbial dysbiosis was found in CKD-N and CKD-H patients. At the phylum level, compared to HCs group, Bacteroidetes decreased but Proteobacteria increased in CKD-H group significantly. Fusobacteria in CKD-N group was significantly lower than HCs group. At genus level, [Eubacterium]_ventriosum_group, Fusobacterium, Agathobacter, Parabacteroides, and Roseburia significantly changed in CKD groups. [Ruminococcus]_gnavus_group was significantly lower in CKD-H group than CKD-N group. Moreover, the fecal metabolome of CKD-N and CKD-H altered significantly. d-glutamine and d-glutamate metabolism, arginine and proline metabolism, histidine metabolism, and lysine biosynthesis were down-regulated in the CKD-N group. Phenylalanine metabolism, arginine and proline metabolism, purine metabolism, and beta-alanine metabolism were up-regulated in the CKD-H group. There was a significant difference between the two CKD groups in phenylalanine metabolism. The abundance change of [Ruminococcus]_gnavus_group, [Eubacterium]_ventriosum_group, UCG-002, Alistipes, and Bifidobacterium had a close correlation with differential metabolites.Conclusion:The gut microbiota and metabolic status undergo significant changes in CKD patients compared to healthy people. Additionally, HUA has been found to impact the gut microbiota of CKD patients, as well as their metabolism. The close association between gut microbiota and metabolites suggests that the former plays a crucial role in metabolism.

Altered Gut Microbiota in Children With Hyperuricemia

Altered Gut Microbiota in Children With Hyperuricemia

The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

Alterations of Gut Microbiota and Metabolome in Early Chronic Kidney Disease Patients Complicated with Hyperuricemia

Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia: probiotics increased

Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development

Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts

The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia

Analysis of Oral Microbiota Revealed High Abundance of Prevotella Intermedia in Gout Patients.

Elevated Interleukin 1β and Interleukin 6 Levels in the Serum of Children With Hyperuricemia.

Alteration of Gut Microbiome and Correlated Amino Acid Metabolism Contribute to Hyperuricemia and Th17-Driven Inflammation in Uox-KO Mice

Clinical Significance of Serum Interleukin-1Β and Interleukin-6 Levels in Childhood Hyperuricemia

Assessing the causal relationships of gut microbial genera with hyperuricemia and gout using two-sample Mendelian randomization

Diagnostic Model for Predicting Hyperuricemia Based on Alterations of the Gut Microbiome in Individuals with Different Serum Uric Acid Levels

Serum Metabolome Analysis by Liquid Chromatography–mass Spectrometry Reveals Differences between Asymptomatic Hyperuricemia and Gout

Urinary Proteomic Characteristics of Hyperuricemia and Their Possible Links with the Occurrence of Its Concomitant Diseases

Alteration of gut microbiota in Henoch-Schönlein purpura children with gastrointestinal involvement

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases

Integrated Analyses of Gut Microbiome and Host Metabolome in Children With Henoch-Schönlein Purpura

Differences in Manifestations and Gut Microbiota Composition Between Patients With Different Henoch-Schonlein Purpura Phenotypes

Prediction and causal inference of hyperuricemia using gut microbiota